Over a decade after starting a16z's biotech and healthcare investing practice, Vijay Pande left the storied Silicon Valley venture-capital firm this summer.
His departure was huge news in the AI bio world, where Pande had been early to computational biology, the Folding@home initiative in 2000 and chairing Stanford's biophysics program before jumping to the VC world.
Pande joined Endpoints on Post-Hoc Live today and shared his outlook on the always-changing AI bio world and the promises and pitfalls of investing in it in 2025.
You can watch here on our YouTube livestream:
We spoke about the latest trends driving AI, and previewed some of the topics for Endpoints' second annual AI Day on Oct. 14. (Sign up for free to watch a livestream or access on-demand recordings here.)
I also had a few questions on Pande's life after a16z, starting with VZVC, his recently announced new VC firm, placing him right back into the thick of investing.
— Andrew Dunn
↧